Drug Trial Radar · NCT07851246
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Jul 9, 2027
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.
Conditions
- Influenza, Human
Interventions
mRNA Seasonal Flu vaccineBiological
One dose of the mRNA Flu vaccine received intramuscularly.
Comparator 1Biological
One dose of the comparator vaccine received intramuscularly.
Comparator 2Biological
One dose of the comparator vaccine received intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titer (GMT) of Antigen 1 TiterTime frame: At Day 29
- GMT of Antigen 2 TiterTime frame: At Day 29
- Percentage of participants with Antigen 1 seroconversion rate (SCR)Time frame: From Day 1 to Day 29
- Number of participants with solicited administration site adverse eventsTime frame: Day 1 to Day 7
- Number of participants with systemic adverse eventsTime frame: Day 1 to Day 7
- Number of participants with unsolicited adverse eventsTime frame: Day 1 to Day 28
- Number of participants with serious adverse events (SAEs)Time frame: Day 1 to Day 181
- Number of participants with adverse events of special interest (AESIs)Time frame: Day 1 to Day 181
- Number of Participants with any Laboratory abnormalitiesTime frame: At Day 1 (pre-dose) and at Day 29 (post - dose)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Glendale, Arizona · Recruiting
GSK Investigational Site
Tucson, Arizona · Recruiting
GSK Investigational Site
San Diego, California · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Meridian, Idaho · Recruiting
GSK Investigational Site
Valparaiso, Indiana · Recruiting
GSK Investigational Site
Lenexa, Kansas · Recruiting
GSK Investigational Site
Hartsdale, New York · Recruiting
GSK Investigational Site
Spartanburg, South Carolina · Recruiting
GSK Investigational Site
DeSoto, Texas · Recruiting
GSK Investigational Site
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.